Positive final results in stroke
CLINUVEL today released positive final results of the open label pilot study...
Read More
CLINUVEL Extends Employment Agreement With CEO
CLINUVEL today announced that it has extended the Employment Agreement with the...
Read More
DNA Repair Communiqué II
In this DNA Repair Communiqué II we delve deeper into the topic...
Read More
First XP-V Patient Treated in CLINUVEL DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read More
Afamelanotide in stroke (AIS) – positive preliminary results
CLINUVEL today released positive preliminary results from its pilot study (CUV801) in...
Read More
DNA Repair Communiqué I
This first Communiqué in a series on DNA forms an introductory foundation,...
Read More
CLINUVEL Expands DNA Repair Program with 2nd DNA Repair Study
CLINUVEL today announced that the first disease-free subjects have received afamelanotide as...
Read More
SCENESSE® continued in Germany
CLINUVEL today announced that it has entered a second agreement with the...
Read More
CLINUVEL completes enrolment in world-first stroke study
CLINUVEL today announced that it has completed enrolment in its world-first study...
Read More
Vitiligo Communiqué IV
CLINUVEL’s fourth Vitiligo Communiqué discusses the long-term consequences, both physical and psychological,...
Read More
First Patient Treated in CLINUVEL DNA Repair Study
Melbourne, Australia, 22 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
CLINUVEL Progresses DNA Repair Program
Melbourne, Australia, 05 October 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Afamelanotide well tolerated by first stroke patients
CLINUVEL’s drug afamelanotide was well tolerated by the first three arterial ischaemic...
Read More
Media Release - First stroke patient treated with afamelanotide
Melbourne, Australia, 07 June 2021 ASX: XETRA-DAX: NASDAQ INTERNATIONAL DESIGNATION: CUV UR9...
Read More
Media Release - CLINUVEL Expands DNA Repair Program
SCENESSE® (afamelanotide 16mg) to be evaluated in xeroderma pigmentosum variant (XP-V) CLINUVEL...
Read More